• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by SeaStar Medical Holding Corporation

    6/27/25 5:08:27 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care
    Get the next $ICU alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    SeaStar Medical Holding Corporation

    (Name of Issuer)


    Common stock, par value $0.0001 per share

    (Title of Class of Securities)


    81256l203

    (CUSIP Number)


    06/20/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    81256l203


    1Names of Reporting Persons

    Mitchell P. Kopin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,803,026.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,803,026.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,803,026.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    81256l203


    1Names of Reporting Persons

    Daniel B. Asher
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,803,026.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,803,026.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,803,026.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    81256l203


    1Names of Reporting Persons

    Intracoastal Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,803,026.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,803,026.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,803,026.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SeaStar Medical Holding Corporation
    (b)Address of issuer's principal executive offices:

    3513 Brighton Blvd, Suite 410, Denver, Colorado 80216
    Item 2. 
    (a)Name of person filing:

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
    (b)Address or principal business office or, if none, residence:

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
    (c)Citizenship:

    Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
    (d)Title of class of securities:

    Common stock, par value $0.0001 per share
    (e)CUSIP No.:

    81256l203
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on June 20, 2025 (the "SPA") (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 23, 2025), each of the Reporting Persons may have been deemed to have beneficial ownership of 1,243,478 shares of Common Stock, which consisted of (i) 1,240,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 3,478 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 1"), and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 11,203,752 shares of Common Stock outstanding as of June 12, 2025, as reported by the Issuer, plus (2) 1,240,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 3,478 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 102,676 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (II) 1,346,154 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 2") because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (III) 1,346,154 shares of Common Stock issuable upon exercise of a third warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA ("Intracoastal Warrant 3") because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (IV) 5,000 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 4") because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock and (V) 94,785 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal ("Intracoastal Warrant 5") because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 4,138,247 shares of Common Stock. (ii) As of the close of business on June 27, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,803,026 shares of Common Stock, which consisted of (i) 1,346,154 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 and (ii) 456,872 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3, and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 11,203,752 shares of Common Stock outstanding as of June 12, 2025, as reported by the Issuer, plus (2) 4,935,385 shares of Common Stock issued at the closing of the transaction contemplated by the SPA, (3) 106,154 Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 1, (4) 1,346,154 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 and (5) 456,872 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3. The foregoing excludes (I) 889,282 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (II) 5,000 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4 because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock and (III) 94,785 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5 because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 2,792,093shares of Common Stock.
    (b)Percent of class:

    9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    1,803,026

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    1,803,026

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Mitchell P. Kopin
     
    Signature:/s/ Mitchell P. Kopin
    Name/Title:Mitchell P. Kopin
    Date:06/27/2025
     
    Daniel B. Asher
     
    Signature:/s/ Daniel B. Asher
    Name/Title:Daniel B. Asher
    Date:06/27/2025
     
    Intracoastal Capital LLC
     
    Signature:/s/ Mitchell P. Kopin
    Name/Title:Mitchell P. Kopin, Manager
    Date:06/27/2025
    Exhibit Information

    Exhibit 1 - Joint Filing Agreement

    Get the next $ICU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ICU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Heel Kenneth was granted 3,000 shares, increasing direct ownership by 61% to 7,940 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:58:51 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Neuman John was granted 3,000 shares, increasing direct ownership by 33% to 12,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:58:22 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Baird Jennifer A was granted 3,000 shares, increasing direct ownership by 83% to 6,620 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:57:09 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SeaStar Medical Holding Corporation

    SCHEDULE 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)

    2/13/26 4:43:46 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical Holding Corporation filed SEC Form 8-K: Other Events

    8-K - SeaStar Medical Holding Corp (0001831868) (Filer)

    1/20/26 4:03:22 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Amendment: SeaStar Medical Holding Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits

    8-K/A - SeaStar Medical Holding Corp (0001831868) (Filer)

    12/23/25 4:44:33 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science

    3/10/26 10:21:44 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

    DENVER, March 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will participate in a fireside CEO chat with David Bautz, Senior Biotech Analyst at Zacks Small-Cap Research, at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 11, 2026. DATE: March 11th TIME: 12:00 pm E.T. REGISTER HERE Available for 1x1 meetings: March 11. Schedule 1x1 Meetings here. The event will be conducted as a live, interactive online forum, offe

    3/9/26 8:35:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

    DENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT). The registry has successfully enrolled 50 patients, and the company will be reporting the 28-day safety results from the SAVE Registry to the FDA upon completion of its analysis of the data. "The early results from the SAVE Regis

    3/5/26 8:20:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Messinger Michael bought $5,098 worth of shares (14,500 units at $0.35), increasing direct ownership by 483% to 17,500 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/11/25 6:49:59 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Van Heel Kenneth bought $30,812 worth of shares (35,000 units at $0.88), increasing direct ownership by 243% to 49,400 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    8/28/25 5:28:58 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Leadership Updates

    Live Leadership Updates

    View All

    SeaStar Medical Announces Appointment of Michael Messinger as CFO

    DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

    11/17/25 8:43:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Financials

    Live finance-specific insights

    View All

    SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Business highlights include: Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI)Commercial use of QUELIMMUNE therapy demonstrates positive survival results as reported from the QUELIMMUNE SAVE Surveillance RegistryNew clinical sites added to expand adult NEUTRALIZE-AKI pivotal trial enrollmentStrengthened the balance sheet, raising $12.4 million to fund future operationsWebcast call today at 4:30 p.m. Eastern Time DENVER, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure

    11/13/25 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025

    DENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Thursday, November 13, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, November 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Dial-in number:To join the conference call via phone, please pre-register online here to receive a telephone number

    11/5/25 10:03:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025

    DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, August 13, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, August 13, 2025, at 4:30 p.m. ET / 2:30 p.m. MTWebcast:The live webcast and replay can be found here.Conference ID:2078693Dial-in numbers:1 (800) 715-9871 within the U.S.1 (646) 307-1963 from outside the U.S.

    8/7/25 10:00:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ICU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care